Reply: High Risk of Gastrointestinal Bleeding on Dual Antiplatelet Treatment

Muthiah Vaduganathan; Deepak L. Bhatt; Byron L. Cryer; Yuyin Liu; Wen Hua Hsieh; Gheorghe Doros; Marc Cohen; Angel Lanas; Thomas J. Schnitzer; Thomas L. Shook; Pablo Lapuerta; Mark A. Goldsmith; Loren Laine; Christopher P. Cannon

doi:10.1016/j.jacc.2016.06.008

Reply: High Risk of Gastrointestinal Bleeding on Dual Antiplatelet Treatment

Muthiah Vaduganathan, Deepak L. Bhatt, Byron L. Cryer, Yuyin Liu, Wen Hua Hsieh, Gheorghe Doros, Marc Cohen, Angel Lanas, Thomas J. Schnitzer, Thomas L. Shook, Pablo Lapuerta, Mark A. Goldsmith, Loren Laine, Christopher P. Cannon

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	981-982
Number of pages	2
Journal	Journal of the American College of Cardiology
Volume	68
Issue number	9
DOIs	https://doi.org/10.1016/j.jacc.2016.06.008
State	Published - Aug 30 2016

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jacc.2016.06.008

Cite this

Vaduganathan, M., Bhatt, D. L., Cryer, B. L., Liu, Y., Hsieh, W. H., Doros, G., Cohen, M., Lanas, A., Schnitzer, T. J., Shook, T. L., Lapuerta, P., Goldsmith, M. A., Laine, L., & Cannon, C. P. (2016). Reply: High Risk of Gastrointestinal Bleeding on Dual Antiplatelet Treatment. Journal of the American College of Cardiology, 68(9), 981-982. https://doi.org/10.1016/j.jacc.2016.06.008

@article{3a929518ad14443bb8961d227896d38b,

title = "Reply: High Risk of Gastrointestinal Bleeding on Dual Antiplatelet Treatment",

author = "Muthiah Vaduganathan and Bhatt, {Deepak L.} and Cryer, {Byron L.} and Yuyin Liu and Hsieh, {Wen Hua} and Gheorghe Doros and Marc Cohen and Angel Lanas and Schnitzer, {Thomas J.} and Shook, {Thomas L.} and Pablo Lapuerta and Goldsmith, {Mark A.} and Loren Laine and Cannon, {Christopher P.}",

note = "Funding Information: Please note: The COGENT trial was funded by Cogentus Pharmaceuticals. The study investigators had full access to the trial database and retained complete control on the decision to pursue publication. The sponsor did not have the right to review or approve this letter. A full list of the COGENT investigators can be found in Bhatt DL et al. N Engl J Med 2010;363:1909-1917. Dr. Bhatt is on the advisory boards of Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, and Regado Biosciences; the board of directors of Boston VA Research Institute and Society of Cardiovascular Patient Care; is chair of the American Heart Association Quality Oversight Committee; is on the data monitoring committees of Duke Clinical Research Institute, Harvard Clinical Research Institute, Mayo Clinic, and Population Health Research Institute; has received honoraria from the American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org ), Belvoir Publications (Editor-in-Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), Harvard Clinical Research Institute (clinical trial steering committee), HMP Communications (Editor-in-Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Population Health Research Institute (clinical trial steering committee), Slack Publications (Chief Medical Editor, Cardiology Today{\textquoteright}s Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), and WebMD (CME steering committees); has a relationship with Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Vice-Chair), and VA CART Research and Publications Committee (Chair); has received research funding from Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Forest Laboratories, Ischemix, Medtronic, Pfizer, Roche, Sanofi, and The Medicines Company; has received royalties from Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald{\textquoteright}s Heart Disease); is site co-investigator for Biotronik, Boston Scientific, and St. Jude Medical; is a trustee of the American College of Cardiology; and has performed unfunded research for Cogentus (Chair of COGENT), FlowCo, PLx Pharma, and Takeda. Dr. Cryer has served as a consultant to Cogent Pharmaceuticals. Dr. Lanas has received an investigator-initiated grant from and served on advisory boards for Bayer Pharma AG. Dr. Shook is an employee of PAREXEL International. Dr. Lapuerta is an employee of Lexicon Pharmaceuticals. Dr. Goldsmith is an employee of Constellation Pharmaceuticals. Dr. Laine has served on the data safety monitoring boards for studies sponsored by Bayer and Bristol-Myers Squibb. Dr. Cannon has served on advisory boards of Bristol-Myers Squibb, Lipimedix, and Pfizer; and has received research funding from Accumetrics, Arisaph, AstraZeneca, Boehringer-Ingelheim, CSL Behring, Essentialis, GlaxoSmithKline, Janssen, Merck, Regeneron, Sanofi, and Takeda. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. ",

year = "2016",

month = aug,

day = "30",

doi = "10.1016/j.jacc.2016.06.008",

language = "English (US)",

volume = "68",

pages = "981--982",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier USA",

number = "9",

}

TY - JOUR

T1 - Reply

T2 - High Risk of Gastrointestinal Bleeding on Dual Antiplatelet Treatment

AU - Vaduganathan, Muthiah

AU - Bhatt, Deepak L.

AU - Cryer, Byron L.

AU - Liu, Yuyin

AU - Hsieh, Wen Hua

AU - Doros, Gheorghe

AU - Cohen, Marc

AU - Lanas, Angel

AU - Schnitzer, Thomas J.

AU - Shook, Thomas L.

AU - Lapuerta, Pablo

AU - Goldsmith, Mark A.

AU - Laine, Loren

AU - Cannon, Christopher P.

N1 - Funding Information: Please note: The COGENT trial was funded by Cogentus Pharmaceuticals. The study investigators had full access to the trial database and retained complete control on the decision to pursue publication. The sponsor did not have the right to review or approve this letter. A full list of the COGENT investigators can be found in Bhatt DL et al. N Engl J Med 2010;363:1909-1917. Dr. Bhatt is on the advisory boards of Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, and Regado Biosciences; the board of directors of Boston VA Research Institute and Society of Cardiovascular Patient Care; is chair of the American Heart Association Quality Oversight Committee; is on the data monitoring committees of Duke Clinical Research Institute, Harvard Clinical Research Institute, Mayo Clinic, and Population Health Research Institute; has received honoraria from the American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org ), Belvoir Publications (Editor-in-Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), Harvard Clinical Research Institute (clinical trial steering committee), HMP Communications (Editor-in-Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Population Health Research Institute (clinical trial steering committee), Slack Publications (Chief Medical Editor, Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), and WebMD (CME steering committees); has a relationship with Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Vice-Chair), and VA CART Research and Publications Committee (Chair); has received research funding from Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Forest Laboratories, Ischemix, Medtronic, Pfizer, Roche, Sanofi, and The Medicines Company; has received royalties from Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease); is site co-investigator for Biotronik, Boston Scientific, and St. Jude Medical; is a trustee of the American College of Cardiology; and has performed unfunded research for Cogentus (Chair of COGENT), FlowCo, PLx Pharma, and Takeda. Dr. Cryer has served as a consultant to Cogent Pharmaceuticals. Dr. Lanas has received an investigator-initiated grant from and served on advisory boards for Bayer Pharma AG. Dr. Shook is an employee of PAREXEL International. Dr. Lapuerta is an employee of Lexicon Pharmaceuticals. Dr. Goldsmith is an employee of Constellation Pharmaceuticals. Dr. Laine has served on the data safety monitoring boards for studies sponsored by Bayer and Bristol-Myers Squibb. Dr. Cannon has served on advisory boards of Bristol-Myers Squibb, Lipimedix, and Pfizer; and has received research funding from Accumetrics, Arisaph, AstraZeneca, Boehringer-Ingelheim, CSL Behring, Essentialis, GlaxoSmithKline, Janssen, Merck, Regeneron, Sanofi, and Takeda. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

PY - 2016/8/30

Y1 - 2016/8/30

UR - http://www.scopus.com/inward/record.url?scp=84995946056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995946056&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2016.06.008

DO - 10.1016/j.jacc.2016.06.008

M3 - Letter

C2 - 27561775

AN - SCOPUS:84995946056

VL - 68

SP - 981

EP - 982

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 9

ER -

Reply: High Risk of Gastrointestinal Bleeding on Dual Antiplatelet Treatment

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this